| Name | Title | Contact Details |
|---|---|---|
Shelby Geyer |
Head of Finance | Profile |
Justin Thompson |
Associate Director, Financial Planning and | Profile |
Candice Taylor |
Vice President, People | Profile |
Marla Bradstock |
Associate Director, Supply Chain | Profile |
Josie Williams |
Human Resources Director | Profile |
OPCO Laboratory Inc is a Fitchburg, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Since 2001, Regent Surgical Health has led the way in developing and managing successful surgery center partnerships. The ASC model is constantly evolving and Regent positions our facility partners to meet these changing market conditions and succeed. Today, a vast majority of our partnerships are Physician/Hospital Joint Ventures. Our experience has led us to develop proprietary ownership models that give both doctors and hospital administrators what they need to ensure long term clinical and financial success. Our success had earned us a reputation as Joint Venture Specialists. Regent has extensive knowledge of the ASC marketplace. We have found successful financial solutions to increase net revenues rather than using out of network strategies, pioneered new procedures such as spine, cardiology, gastric banding, and knee replacements into the ASC environment, and developed both majority and minority hospital partnerships. At Regent, our track record for successful ASC Turnarounds, De Novos, and Joint Ventures is unmatched.
Vitrolife AB is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Englewood, CO. To find more information about Vitrolife AB, please visit www.vitrolife.com
Cofounded by Frank M. Reynolds, MIT`s Dr. Robert S. Langer, Katrin Holzhaus, and Dr. Jason Criscione, PixarBio researches and develops targeted delivery systems for drugs, cells, or biologics to treat pain, epilepsy, Parkinson`s disease, and spinal cord injury.
Wesana Health helps people transcend barriers in mental health and performance. We innovate in care development through our therapies and patent-pending protocols, and in care delivery through activating a new multidisciplinary, technology-supported clinical model.